Specialty biotech company Advanced Enzymes acquires HTGF Portfolio company evoxx technologies
The industrial biotechnology company evoxx technologies GmbH has become a part of the leading specialty biotech company Advanced Enzyme Technologies Limited. Both companies announced that they have entered into a binding agreement about the acquisition of 100% stake in evoxx technologies.
evoxx technologies is proud to announce that it will become part of the global enzyme manufacturing company Advanced Enzyme Technologies Limited. evoxx and its team of 35+ scientists & technicians across the two sites in Germany, Monheim am Rhein and Potsdam, will be the Research & Development centers and sales points of Advanced Enzymes in Europe. V.L. Rathi, Chairman, Advanced Enzymes, said,
“evoxx has a great strategic fit for us. With evoxx we significantly expand our R&D capabilities and also strengthen our European presence.”
The acquisition will give Advanced Enzymes a stronger foothold in Germany and in Europe and will also help strengthen its Research & Development capabilities. The acquisition will also help Advanced Enzymes expand its enzyme portfolio & business in biocatalysis and food applications.
“Together with the strong partners in India and USA, the portfolio of industrial enzymes will be larger and more attractive for the existing and future customers of evoxx. Furthermore, the production plants and production knowledge of Advanced Enzymes will help evoxx deliver enzymes in industrial scale,” said Dr. Thorsten Eggert, CEO of evoxx technologies.
Notwithstanding the acquisition, evoxx will ensure continuity in cooperative projects with customers and partners. The proprietary technology platform of evoxx technologies to develop tailor-made enzymes and processes for various industries will be still available in the future.
About evoxx technologies GmbH
evoxx technologies GmbH, a German industrial biotechnology company, is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high growth markets addressing consumer needs in the global food health & wellness sector and consumer products markets. Product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation. evoxx industrial partners and customers benefit from the unique metagenomics libraries, the enzyme and carbohydrate development skills and tech-transfer and production capabilities. evoxx is located on the Creative Campus in Monheim am Rhein and on the Biotech Campus Hermannswerder in Potsdam.
Dr. Thorsten Eggert
Managing Director, CEO
evoxx technologies GmbH
40789 Monheim am Rhein
Tel.: +49 2173 4099-411
Fax: +49 2173 4099-440
Managing Director, CSO/ Business Development
evoxx technologies GmbH
Tel.: +49 331 2000-110
Fax: +49 331 2000 111
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited is a research driven company with global leadership in the manufacturing of enzymes, incorporated in 1989. However, its journey began, when founder Late Shri L.C. Rathi set up India’s first enzyme manufacturing plant in 1958. Since then, the company has continued to grow with that same entrepreneurial and innovative spirit and is today, the largest producer of enzymes in Central Asia. It is committed to serve the human nutrition, animal nutrition and bio-processing industries with its enzymatic solutions. The company aims to provide side-effect free healthcare and eco-safe industrial solutions to its customers globally.
Equipped with state-of-the-art 7 manufacturing facilities and 5 research & development centres across India and US, Advanced Enzymes exports to 45+ countries across 6 continents, and provides customized & effective enzyme solutions coupled with the best in technical advice & superior service.
High-Tech Gründerfonds (HTGF) is Germany’s most active seed stage investor. With about EUR 820 million under management in three funds we provide financing for technology-driven companies active in a wide range of fields, including robotics, IoT and energy, Medtech and Biotech, chemicals and software. Investors in this public-private partnership include the German Federal Ministry of Economics and Energy, the KfW, and strategic corporate investors.